HOTH News and Press, Hoth Therapeutics Inc. From 05/05/21

Hoth Therapeutics and Virginia Commonwealth University Expand Research Agreement for COVID-19 Therapeutic PR Newswire NEW YORK , May 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expa...

Hoth Therapeutics (HOTH) intends to pursue development of its HT-KIT mRNA Frame Shifting Therapeutic for multiple orphan diseases in U.S.HT-KIT targets a shared cell signaling pathway that may have therapeutic potential for multiple rare cancers, including:Aggressive systemic mastoc...

Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers PR Newswire NEW YORK , May 3, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceu...

Hoth Therapeutics (HOTH) starts its First in Human clinical trial investigating topical BioLexa for the treatment of mild to moderate atopic dermatitis, also known as eczema. The trial is being conducted in Australia. For further details see: Hoth Therapeutics' human trial underway eval...

Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underway PR Newswire NEW YORK , April 22, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused ...

Shares of Hoth Therapeutics Inc. (NASDAQ:HOTH) traded at a new 52-week low today of $1.51. This new low was reached on above average trading volume as 14.2 million shares traded hands, while the average 30-day volume is approximately 4.1 million shares. Hoth Therapeutics Inc is a develop...

Gainers: Purple Biotech (PPBT) +9%, NeuroBo Pharmaceuticals (NRBO) +7%, Obalon Therapeutics (OBLN) +7%, Dare Bioscience (DARE) +4%, Hoth Therapeutics (HOTH) +2%.Losers: Syndax Pharmaceuticals (SNDX) -28%, Zai Lab (ZLAB) -13%, KalVist...

Hoth Therapeutics (HOTH) shares surge more than 17% during premarket trading after the company announces that its novel anti-cancer therapeutic exhibited positive results in humanized mast cell neoplasm models, representative in vitro and in vivo models for aggressive...

Hoth Therapeutics Announces its mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell-Derived Cancers Reports Preclinical Data Significantly Reduces Tumor Growth in a Humanized Mast Cell Neoplasm Model for Treatment of Aggressive, Mast Cell-Derived Can...

Hoth Therapeutics Inc. (NASDAQ:HOTH) traded today at a new 52-week low of $1.50. Approximately 14.2 million shares have changed hands today, as compared to an average 30-day volume of 4.1 million shares. There is potential upside of 27.6% for shares of Hoth Therapeutics Inc. based on a c...